Drug Trial Radar · NCT05772676
The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting
Last checked: Nov 20, 2026Latest source record: Mar 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
400
Actual
Start
Dec 1, 2022
Primary completion
Jan 1, 2023
Study completion Apr 1, 2023
Sponsor
- Lead sponsor
- Hospital General TlahuacGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Mar 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy of Aprepitant + standard antiemetic regimen in reducing postoperative nausea and vomiting after laparoscopic gastric sleeve versus placebo + standard antiemetic regimen
Conditions
- Obesity
- Nausea and Vomiting, Postoperative
Interventions
AprepitantDrug
80 or 125 mg tablet + standard antiemetic regimen, once two hours before surgery
PlaceboOther
Placebo + standard antiemetic regimen, once two hours before surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient's postoperative nausea and vomiting evaluation at 0 hrs (Rhodes index)Time frame: 0 postoperative hours
- Patient's postoperative nausea and vomiting evaluation at 6 hrs (Rhodes index)Time frame: 6 postoperative hours
- Patient's postoperative nausea and vomiting evaluation at 12 hrs (Rhodes index)Time frame: 12 postoperative hours
- Patient's postoperative nausea and vomiting evaluation at 24 hrs (Rhodes index)Time frame: 24 postoperative hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital General Tlahuac
Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.